The results of a newly reported study may offer scientists a strategy for mitigating the negative side effects associated with intravenous injection of nanoparticles used in medicine. The new approach ...
Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
Initial study data indicate GEM103 can regulate complement activity in geographic atrophy secondary to dry age-related macular degeneration and has a tolerable safety profile, according to a press ...
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing innovative drugs to treat rare diseases and targeted cancers in ...
Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...
Most people infected with the SARS-CoV-2 virus recover after the acute illness. However, a significant proportion of infected individuals develop long-lasting symptoms with a wide range of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback